CLINICAL TRIALS PROFILE FOR GLIPIZIDE
✉ Email this page to a colleague
All Clinical Trials for glipizide
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00094770 ↗ | An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (0431-024) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2004-09-01 | The purpose of this investigational study is to determine the safety and effectiveness of an investigational drug in patients with type 2 diabetes mellitus (a specific type of diabetes). |
| NCT00095056 ↗ | An Investigational Drug in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (0431-028)(COMPLETED) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2004-10-01 | The purpose of this study is to determine the safety and tolerability of an investigational drug in patients with Type 2 Diabetes Mellitus (a specific type of diabetes) and Chronic Renal Insufficiency (inadequate kidney function). |
| NCT00116831 ↗ | Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 Diabetes | Completed | GlaxoSmithKline | Phase 3 | 2005-01-01 | The purpose of this study is to test the safety and effectiveness of rosiglitazone against a sulfonylurea in reducing or slowing the development of atherosclerosis in the blood vessels of the heart. |
| NCT00347100 ↗ | Insulin Glargine in Type 2 Diabetic Patients | Completed | Sanofi | Phase 4 | 2006-06-01 | Primary: - To investigate the efficacy of insulin glargine (in terms of change in A1c from baseline to endpoint A1c < 7%) Secondary: - To investigate the safety of insulin glargine (in terms of hypoglycaemia, including symptomatic, non-symptomatic and nocturnal hypoglycaemia) - To investigate whether beta cell function is preserved if this therapy is initiated before 2nd OAD (oral anti-diabetic drug) failure |
| NCT00350779 ↗ | Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2006-06-12 | A clinical study to determine the safety and efficacy of sitagliptin in patients with Type 2 Diabetes Mellitus who have inadequate glycemic control on metformin/peroxisome proliferator-activated receptor gamma (PPARg) agonist combination therapy. |
| NCT00509236 ↗ | Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease (MK-0431-073 AM1) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2007-10-19 | The purpose of the study is to compare sitagliptin and glipizide in lowering blood sugar in participants with type-2 diabetes mellitus (T2DM) and end-stage renal disease on dialysis who do not have adequate glycemic control. |
| NCT00509262 ↗ | Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (MK-0431-063 AM1) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2007-10-09 | The purpose of the study is to compare how sitagliptin and glipizide lower blood glucose levels in participants with moderate or severe renal insufficiency. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for glipizide
Condition Name
Clinical Trial Locations for glipizide
Trials by Country
Clinical Trial Progress for glipizide
Clinical Trial Phase
Clinical Trial Sponsors for glipizide
Sponsor Name
